

**Aptamer-based imaging:** Wang and Farokhzad provide an overview of the use of these single-stranded oligonucleotides as targeting ligands and their application in molecular diagnosis and therapy. . . . . **Page 353**

**Occult primary NET imaging:** Schillaci looks at radiopharmaceuticals available for imaging unknown primary neuroendocrine tumors and previews an article in this issue of *JNM* on the advantages of <sup>18</sup>F-DOPA PET/CT in this setting. . . . . **Page 357**

**Safety of repeated radioembolization:** Zarva and colleagues assess the safety of repeated <sup>90</sup>Y radioembolization with resin microspheres in patients with extensive primary and secondary liver tumors after failure of first radioembolization. . . . . **Page 360**

**<sup>18</sup>F-FDOPA and NETs of unknown origin:** Imperiale and colleagues evaluate the performance of <sup>18</sup>F-DOPA PET/CT in detecting and further characterizing primary neuroendocrine tumors not seen on other morphologic or functional imaging. . . . . **Page 367**

**PET/CT vs PET/MR in lung cancer staging:** Heusch and colleagues compare a dedicated pulmonary <sup>18</sup>F-FDG PET/MR imaging protocol with <sup>18</sup>F-FDG PET/CT for primary and loco-regional lymph node staging in patients with non-small cell lung cancer. . . . . **Page 373**

**Preoperative PET and NSCLC:** Zeliadt and colleagues examine the real-world effectiveness of PET in avoiding unnecessary surgery in patients newly diagnosed with non-small cell lung cancer. . . . . **Page 379**

**PET/CT and KRAS mutations:** Miles and colleagues explore the potential for multi-functional imaging to provide a signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog gene mutations in human colorectal cancer. . . . . **Page 386**

**PET/CT in noninfected vascular grafts:** Keidar and colleagues describe the incidence and patterns of <sup>18</sup>F-FDG uptake over time in noninfected vascular grafts, with a focus on prosthetic material and location. . . . . **Page 392**

**PET imaging of VACHT:** Petrou and colleagues report on human imaging with <sup>18</sup>F-FEOBV, a vesamicol derivative that binds selectively to the vesicular acetylcholine transporter, and detail radiation dosimetry, biodistribution,

safety, brain kinetics, and quantitative analysis methods. . . . . **Page 396**

**Monte Carlo dosimetry for SIRT:** Petitguillaume and colleagues present a 3D dosimetry technique based on patient-specific data for optimization of personalized Monte Carlo dosimetry in <sup>90</sup>Y selective internal radiation therapy for unresectable hepatic cancer. . . . . **Page 405**

**Tumor texture, SUV, and volume in PET:** Orlhac and colleagues investigate texture indices derived from gray-level histograms and their relationship with standardized uptake value, metabolic tumor volume, and total lesion glycolysis in 3 different tumor types. . . . . **Page 414**

**PET and NMDA receptors:** McGinness and colleagues characterize the kinetic behavior of <sup>18</sup>F-GE-179, a novel radioligand that selectively binds to the open/active state of the *N*-methyl *D*-aspartate receptor channels, which play a key role in a range of neurologic processes. . . . . **Page 423**

**PET/CT and HPV+ OPSCC:** Subramaniam and colleagues provide an educational overview of the evolving role of <sup>18</sup>F-FDG PET/CT in the management of patients with human papilloma virus-positive oropharyngeal squamous cell cancer. . . . . **Page 431**

**Propranolol and <sup>18</sup>F-FDG uptake inhibition:** Kang and colleagues explore the relationship between activation of  $\beta$ -adrenoceptors and expression of glucose transporter-1 and hexokinase-2 and discuss the potential effects of this relationship on <sup>18</sup>F-FDG PET imaging in breast cancer. . . . . **Page 439**

**Integrin  $\alpha_v\beta_3$  in pancreatic cancer:** Trajkovic-Arsic and colleagues report on the unexplored potential of  $\alpha_v\beta_3$  integrin-targeted multimodal molecular imaging for detection of pancreatic ductal adenocarcinoma in genetically engineered mouse models. . . . . **Page 446**

**ImmunoPET with anti-PSCA minibody:** Knowles and colleagues detail the development and validation of agents using <sup>124</sup>I- and <sup>89</sup>Zr-labeled anti-prostate stem cell antigen A11 minibodies and evaluate their use for quantitative immunoPET imaging of prostate cancer. . . . . **Page 452**

**Serotonergic metabolism in pancreas:** Eriksson and colleagues investigate the feasibility of quantitative noninvasive imaging of serotonergic metabolism in the endocrine pancreas using the PET tracer <sup>11</sup>C-5-HTP. . . . . **Page 460**

**Imaging microglial activation:** Dickens and colleagues describe a reproducible lipopolysaccharide-induced model of acute central nervous system inflammation and compare the performance of <sup>18</sup>F-GE-180, a translocator protein ligand, with that of <sup>11</sup>C-(*R*)-PK11195 in detection of activated microglial cells and astrocytes. . . . . **Page 466**

**Imaging MC-I in the brain:** Tsukada and colleagues evaluate a novel probe for quantitative PET assessment of mitochondria complex 1 activity and associated ischemic damage in the living brain. . . . . **Page 473**

**Estrogen receptor imaging in rats:** Khayum and colleagues determine whether estrogen receptors can be measured in the rat brain with <sup>18</sup>F-FES PET and whether tracer uptake is affected by endogenous estrogen. . . . . **Page 481**

**Improved complexes for hypoxia imaging:** Handley and colleagues report on evaluation and performance of 2 promising <sup>64</sup>Cu-ATSM analog complexes for PET imaging of hypoxic myocardium. . . . . **Page 488**

**Small-animal PET with isolated perfused heart:** Yamane and colleagues report on a technique combining the Langendorff method of isolated rat heart perfusion with high-resolution small-animal PET to facilitate reliable quantification of myocardial tracer kinetics. . . . . **Page 495**

**TEM1 immuno-PET:** Chacko and colleagues detail the preparation and evaluation of a novel <sup>124</sup>I-labeled humanized monoclonal antibody, looking at its ability to specifically and sensitively detect vascular cells expressing tumor endothelial marker 1 in vivo. . . . . **Page 500**

**XTEN-annexin A5:** Haeckel and colleagues present a method to extend imaging probe blood life with a long-circulating hydrophilic peptide without PEGylation, thereby simplifying synthesis and avoiding inactivation of annexin A5 and potential adverse effects of polyethylene glycol. . . . . **Page 508**

**Comparison of 4 PET hypoxia tracers:** Carlin and colleagues compare the imaging characteristics and hypoxia selectivity of 4 PET radiotracers in a murine xenograft tumor model using small-animal PET imaging and combined ex vivo autoradiography and fluorescence immunohistochemistry. . . . . **Page 515**